Daily Pill Shows Promise in Slowing Type 1 Diabetes
A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 diabetes…